Research Article

ER81 Expression in Breast Cancers and Hyperplasia

Table 3

Comparison between ER81 expression and clinical data in breast cancers.

š‘› ER81 negative (%)ER81 positive ( š‘› , %)*P ( šœ’ 2 )

Age, years
ā€ƒā‰¤504822 (45.8)26 (54.2).814
ā€ƒ>503316 (48.5)17 (51.5)
Menopause
ā€ƒBefore4622 (47.8)24 (52.2).483
ā€ƒAfter3514 (40.0)21 (60.0)
Tumor size, cm
ā€ƒā‰¤2157 (46.7)8 (53.3).138
ā€ƒ2ā€“55528 (50.9)27 (49.1)
ā€ƒ>5112 (18.2)9 (81.8)
Nodal status
ā€ƒNegative4318 (41.9)25 (58.1).463
ā€ƒPositive3819 (50.0)19 (50.0)
Histological stage
ā€ƒI106 (60.0)4 (40.0).246
ā€ƒII5414 (25.9)30 (74.1)
ā€ƒIII176 (35.3)11 (64.7)
ER
ā€ƒNegative251 (4.0)24 (96.0).001
ā€ƒPositive5622 (39.3)34 (60.7)
PR
ā€ƒNegative283 (10.7)25 (89.3).010
ā€ƒPositive5320 (37.7)33 (62.3)
HER2 amplification
ā€ƒNegative5319 (35.8)34 (64.2).041
ā€ƒPositive284 (14.3)24 (85.7)

*Breast cancer tissues with I R S ā‰„ 3 were considered as ER81 positive expression.